Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ZNTL 
Zentalis Pharmaceuticals Llc (ZNTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/15/2025: ZNTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $5.31
1 Year Target Price $5.31
| 3 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.57% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.15M USD | Price to earnings Ratio - | 1Y Target Price 5.31 |
Price to earnings Ratio - | 1Y Target Price 5.31 | ||
Volume (30-day avg) 10 | Beta 1.75 | 52 Weeks Range 1.01 - 3.33 | Updated Date 12/16/2025 |
52 Weeks Range 1.01 - 3.33 | Updated Date 12/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -567.77% |
Management Effectiveness
Return on Assets (TTM) -24.51% | Return on Equity (TTM) -49.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -142837910 | Price to Sales(TTM) 3.77 |
Enterprise Value -142837910 | Price to Sales(TTM) 3.77 | ||
Enterprise Value to Revenue 7.77 | Enterprise Value to EBITDA -2.31 | Shares Outstanding 72250779 | Shares Floating 50093633 |
Shares Outstanding 72250779 | Shares Floating 50093633 | ||
Percent Insiders 13.52 | Percent Institutions 72.47 |
About Zentalis Pharmaceuticals Llc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-03 | CEO, President & Director Ms. Julie M. Eastland M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 166 | Website https://zentalis.com |
Full time employees 166 | Website https://zentalis.com | ||
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.